Understand the source comparison
Cagrilintide Alternatives 2026: Mechanism Comparison
Tirzepatide GLP-1 + GIP 20.9% at 72 weeks (SURMOUNT-1) ~5 days FDA-approved (Mounjaro, Zepbound) Most clinically validated dual agonist; weekly dosing; GI side effects peak during titration Retatrutide GLP-1 + GIP + Glucagon 24.2% at 48 weeks (Phase 2) ~6 days
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Tirzepatide
- GLP-1 + GIP
- 20.9% at 72 weeks (SURMOUNT-1)
- ~5 days
- FDA-approved (Mounjaro, Zepbound)
- Most clinically validated dual agonist; weekly dosing; GI side effects peak during titration
- Retatrutide
- GLP-1 + GIP + Glucagon
- 24.2% at 48 weeks (Phase 2)
- ~6 days
- Investigational (Phase 3)
- Highest weight reduction observed; glucagon component increases thermogenesis; investigational-only
- Survodutide
- GLP-1 + Glucagon
- 15.7% at 46 weeks (Phase 2)
- Investigational / 503B compounding
- Accessible through licensed compounding; glucagon agonism without GIP; lower nausea vs triple agonists
- Mazdutide
- 16.1% at 24 weeks (Phase 2)
- ~7 days
- Similar profile to survodutide; weekly injection; thermogenic effect from glucagon receptor
- Cagrilintide
- Amylin only
- 6.2% at 32 weeks (REWIND)
- Investigational (CagriSema Phase 3)
- Modest standalone efficacy; designed for combination therapy; delays gastric emptying
- Davalintide
- Amylin (selective analog)
- 4–6% at 20 weeks (Phase 2)
- ~4 days
- Investigational (early phase)
- Lower nausea than cagrilintide but similar modest efficacy; mechanism limited to amylin pathway